Expert Review of Anti-infective Therapy最新文献_第10页

The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants 新型口服抗病毒治疗对奥米克隆 XBB 亚变体占优势期间非住院高危 COVID-19 患者的有效性

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-04-03 DOI: 10.1080/14787210.2024.2339398

Chi-Kuei Hsu, Wan-Hsuan Hsu, Bo-Wen Shiau, Ya-Wen Tsai, Jheng-Yan Wu, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai

引用次数: 0

Evaluation of Tamarix nilotica Fractions in Combating Candida albicans Infections. 评估柽柳提取物在抗白色念珠菌感染中的作用。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-04-01 Epub Date: 2023-07-04 DOI: 10.1080/14787210.2023.2232112

Ehssan Moglad, Engy Elekhnawy, Walaa A Negm, Fatma A Mokhtar, Reem Binsuwaidan, Nashwah G M Attallah, Eman Ahmed, Sameh Magdeldin, Omnia Momtaz Al-Fakhrany

{"title":"Evaluation of Tamarix nilotica Fractions in Combating Candida albicans Infections.","authors":"Ehssan Moglad, Engy Elekhnawy, Walaa A Negm, Fatma A Mokhtar, Reem Binsuwaidan, Nashwah G M Attallah, Eman Ahmed, Sameh Magdeldin, Omnia Momtaz Al-Fakhrany","doi":"10.1080/14787210.2023.2232112","DOIUrl":"10.1080/14787210.2023.2232112","url":null,"abstract":"Objectives: Evaluation of the antifungal properties of Tamarix nilotica fractions against Candida albicans clinical isolates.Methods: The in vitro antifungal potential was evaluated by agar well diffusion and broth microdilution methods. The antibiofilm potential was assessed by crystal violet, scanning electron microscopy (SEM), and qRT-PCR. The in vivo antifungal activity was evaluated by determining the burden in the lung tissues of infected mice, histopathological, immunohistochemical studies, and ELISA.Results: Both the dichloromethane (DCM) and ethyl acetate (EtOAc) fractions had minimum inhibitory concentration (MIC) values of 64-256 and 128-1024 μg/mL, respectively. SEM examination showed that the DCM fraction decreased the biofilm formation capacity of the treated isolates. A significant decline in biofilm gene expression was observed in 33.33% of the DCM-treated isolates. A considerable decline in the CFU/g lung count in infected mice was observed, and histopathological examinations revealed that the DCM fraction maintained the lung tissue architecture. Immunohistochemical investigations indicated that the DCM fraction significantly (p < 0.05) decreased the expression of pro-inflammatory and inflammatory cytokines (TNF-α, NF-kB, COX-2, IL-6, and IL-1β) in the immunostained lung sections. The phytochemical profiling of DCM and EtOAc fractions was performed using Liquid chromatography-mass spectrometry (LC-ESI-MS/MS).Conclusion: T. nilotica DCM fraction could be a significant source of natural products with antifungal activity against C. albicans infections.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"241-251"},"PeriodicalIF":5.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9746945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Waking up to the Naegleria threat: urgent measures needed to protect public health in Pakistan. 警惕奈格勒氏菌的威胁：保护巴基斯坦公众健康所需的紧急措施。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-04-01 Epub Date: 2024-01-10 DOI: 10.1080/14787210.2024.2304055

Ifrah Ata, Nabeel Riaz, Fariah Ata, Umer Farooq, Tauqeer Hussain Mallhi

引用次数: 0

Improving management of febrile neutropenia in oncology patients: the role of artificial intelligence and machine learning. 改善肿瘤患者发热性中性粒细胞减少症的管理：人工智能和机器学习的作用。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-08 DOI: 10.1080/14787210.2024.2322445

Antonio Gallardo-Pizarro, Olivier Peyrony, Mariana Chumbita, Patricia Monzo-Gallo, Tommaso Francesco Aiello, Christian Teijon-Lumbreras, Emmanuelle Gras, Josep Mensa, Alex Soriano, Carolina Garcia-Vidal

{"title":"Improving management of febrile neutropenia in oncology patients: the role of artificial intelligence and machine learning.","authors":"Antonio Gallardo-Pizarro, Olivier Peyrony, Mariana Chumbita, Patricia Monzo-Gallo, Tommaso Francesco Aiello, Christian Teijon-Lumbreras, Emmanuelle Gras, Josep Mensa, Alex Soriano, Carolina Garcia-Vidal","doi":"10.1080/14787210.2024.2322445","DOIUrl":"10.1080/14787210.2024.2322445","url":null,"abstract":"Introduction: Artificial intelligence (AI) and machine learning (ML) have the potential to revolutionize the management of febrile neutropenia (FN) and drive progress toward personalized medicine.Areas covered: In this review, we detail how the collection of a large number of high-quality data can be used to conduct precise mathematical studies with ML and AI. We explain the foundations of these techniques, covering the fundamentals of supervised and unsupervised learning, as well as the most important challenges, e.g. data quality, 'black box' model interpretation and overfitting. To conclude, we provide detailed examples of how AI and ML have been used to enhance predictions of chemotherapy-induced FN, detection of bloodstream infections (BSIs) and multidrug-resistant (MDR) bacteria, and anticipation of severe complications and mortality.Expert opinion: There is promising potential of implementing accurate AI and ML models whilst managing FN. However, their integration as viable clinical tools poses challenges, including technical and implementation barriers. Improving global accessibility, fostering interdisciplinary collaboration, and addressing ethical and security considerations are essential. By overcoming these challenges, we could transform personalized care for patients with FN.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"179-187"},"PeriodicalIF":5.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140059059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interaction of zincite, alpha-terpineol, geranyl acetate, linalool, myrcenol, terpinolene, and thymol with virulence factors of Escherichia coli, Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Staphylococcus aureus. 锌石、α-松油醇、乙酸香叶酯、芳樟醇、月桂烯醇、萜品醇和百里酚与大肠杆菌、结核分枝杆菌、绿脓杆菌和金黄色葡萄球菌毒力因子的相互作用。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-04-01 Epub Date: 2023-07-23 DOI: 10.1080/14787210.2023.2238123

Mehran Alavi, Morahem Ashengroph

{"title":"Interaction of zincite, alpha-terpineol, geranyl acetate, linalool, myrcenol, terpinolene, and thymol with virulence factors of Escherichia coli, Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Staphylococcus aureus.","authors":"Mehran Alavi, Morahem Ashengroph","doi":"10.1080/14787210.2023.2238123","DOIUrl":"10.1080/14787210.2023.2238123","url":null,"abstract":"Background: Based on gas chromatography - mass spectrometry (GC-MS) results of a previous study, six metabolites including alpha-terpineol, geranyl acetate, linalool, myrcenol, terpinolene, and thymol showed significantly higher amounts relative to other metabolites.Methods: A continuation of the previous study, the interaction of these metabolites with the main virulence factors of P. aeruginosa (pseudomonas elastase and exotoxin A), Staphylococcus aureus (alpha-hemolysin and protein 2a), Mycobacterium tuberculosis (ESX-secreted protein B and the serine/threonine protein kinase), and Escherichia coli (heat-labile enterotoxin and Shiga toxin) were evaluated by molecular docking study and molecular simulation.Results: In the case of Shiga toxin, higher and lower binding affinities were related to alpha-terpinolene and zincite with values of -5.8 and -2.6 kcal/mol, respectively. For alpha-hemolysin, terpinolene and alpha-terpinolene demonstrated higher binding affinities with similar energies of -5.9 kcal/mol. Thymol and geranyl acetate showed lower binding energy of -5.7 kcal/mol toward protein 2a. Furthermore, thymol had a higher binding affinity toward heat-labile enterotoxin and ESX-secreted protein B with values of -5.9 and -6.1 kcal/mol, respectively.Conclusions: It is concluded that the availability of secondary metabolites of A. haussknechtii surrounding zinc oxide (ZnO) NPs can hinder P. aeruginosa by inactivating Pseudomonas elastase and exotoxin.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"253-272"},"PeriodicalIF":5.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9852444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study. 全口服含贝达喹啉方案治疗小儿多药/利福平耐药结核病的疗效和安全性:一项多中心、回顾性、队列研究

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-04-01 Epub Date: 2023-11-22 DOI: 10.1080/14787210.2023.2285917

Wen-Wen Sun, Ming Yang, Xiao-Hong Chen, Li-Chao Fan, Hao-Yu Wu, Shao-Jun Zhang, Yu Chen, Lin Fan

{"title":"Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study.","authors":"Wen-Wen Sun, Ming Yang, Xiao-Hong Chen, Li-Chao Fan, Hao-Yu Wu, Shao-Jun Zhang, Yu Chen, Lin Fan","doi":"10.1080/14787210.2023.2285917","DOIUrl":"10.1080/14787210.2023.2285917","url":null,"abstract":"Objective: The study aimed to observe the efficacy and safety of an all-oral bedaquiline (BDQ)-containing regimen for pediatric multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) through a multicenter, retrospective study in China.Methods: In the study, pediatric patients receiving all-oral BDQ-containing regimen (BDQ group) with clinical matched control group were included, the control group received an injection-containing regimen. The treatment outcomes and the incidence of adverse events (AEs) were compared and analyzed.Results: 79 pediatric patients were enrolled, including 37 cases in BDQ group and 42 cases in the control group, the median age was 12 {8-16} and 11 {9-15} in both groups respectively. Favorable treatment outcome and cure rate in BDQ group were significantly higher than those in control group (100%vs 83.3%, p 0.03; 94.6%vs 63.3%, p 0.00). Median time of sputum culture conversion in BDQ group was significantly shorter than that in the control group (4 weeks vs 8 weeks, p 0.00). The incidence of AEs in the BDQ group was significantly less than that in the control group (48.6% vs 71.4%, p 0.03). No AEs leading to treatment discontinuation of BDQ occurred.Conclusions: The all-oral BDQ-containing regimens may be effective and safe in the Chinese pediatric population.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"219-227"},"PeriodicalIF":5.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bacterial co-infections, secondary infections and antimicrobial use among hospitalized COVID-19 patients in the sixth wave in Pakistan: findings and implications. 巴基斯坦第六波 COVID-19 住院患者的细菌合并感染、继发感染和抗菌药物使用情况：研究结果和影响。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-04-01 Epub Date: 2024-01-22 DOI: 10.1080/14787210.2023.2299387

Zia Ul Mustafa, Arfa Batool, Hadia Ibrar, Muhammad Salman, Yusra Habib Khan, Tauqeer Hussain Mallhi, Johanna C Meyer, Brian Godman, Catrin E Moore

{"title":"Bacterial co-infections, secondary infections and antimicrobial use among hospitalized COVID-19 patients in the sixth wave in Pakistan: findings and implications.","authors":"Zia Ul Mustafa, Arfa Batool, Hadia Ibrar, Muhammad Salman, Yusra Habib Khan, Tauqeer Hussain Mallhi, Johanna C Meyer, Brian Godman, Catrin E Moore","doi":"10.1080/14787210.2023.2299387","DOIUrl":"10.1080/14787210.2023.2299387","url":null,"abstract":"Introduction: Previous studies in Pakistan have shown considerable over prescribing of antibiotics in patients hospitalized with COVID-19 despite very low prevalence of bacterial infections. Irrational use of antibiotics will worsen antimicrobial resistance (AMR).Methods: Retrospective analysis of medical records of patients in the COVID-19 wards of three tertiary care hospitals to assess antibiotic use during the sixth COVID-19 wave.Results: A total of 284 patients were included, most were male (66.9%), aged 30-50 years (50.7%) with diabetes mellitus the most common comorbidity. The most common symptoms at presentation were cough (47.9%) and arthralgia-myalgia (41.5%). Around 3% were asymptomatic, 34.9% had mild, 30.3% moderate, and 23.6% had severe disease, with 8.1% critical. Chest X-ray abnormalities were seen in 43.3% of patients and 37% had elevated white cell counts, with 35.2% having elevated C-reactive protein levels. Around 91% COVID-19 patients were prescribed antibiotics during their hospital stay, with only a few with proven bacterial co-infections or secondary bacterial infections. Most antibiotics were from the 'Watch' category (90.8%) followed by the 'Reserve' category (4.8%), similar to previous COVID-19 waves.Conclusion: There continued to be excessive antibiotics use among hospitalized COVID-19 patients in Pakistan. Urgent measures are needed to address inappropriate prescribing including greater prescribing of Access antibiotics where pertinent.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"229-240"},"PeriodicalIF":5.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139037546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized care approaches to hepatitis C therapy: recent advances and future directions. 丙型肝炎治疗的个性化护理方法：最新进展和未来方向。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-11 DOI: 10.1080/14787210.2024.2328336

Nicola Schiano Moriello, Biagio Pinchera, Ivan Gentile

{"title":"Personalized care approaches to hepatitis C therapy: recent advances and future directions.","authors":"Nicola Schiano Moriello, Biagio Pinchera, Ivan Gentile","doi":"10.1080/14787210.2024.2328336","DOIUrl":"10.1080/14787210.2024.2328336","url":null,"abstract":"Introduction: The introduction of direct-acting antivirals (DAAs) has significantly transformed the therapeutic landscape for chronic C hepatitis virus (HCV) infection. However, there is still room for further improvement in optimizing therapy efficacy and minimizing adverse effects.Areas covered: This review is devoted to the rationale for adopting a personalized approach to HCV therapy. Specifically, we explore the role of host-related factors, such as sex or the presence of comorbidities. We thoroughly examine the implications of commonly encountered comorbidities, including HIV infection, chronic renal disease, liver cirrhosis, and other chronic viral hepatitis infections. Additionally, we discuss the prevalent drug-to-drug interactions between DAAs and other medications, while providing guidance on their management. Finally, we investigate viral-related issues that can influence treatment outcomes, such as viral genotype, quasi-species, and the presence of resistance-associated mutations.Expert opinion: Despite pivotal trials demonstrating efficacy rates exceeding 90% for currently available DAA regimens, there are still opportunities to optimize therapy outcomes and tailor treatment to each patient. This can be achieved through a meticulous evaluation of the patient's specific clinical conditions and comorbidities, a vigilant approach to manage potential drug interactions, and diligent patient follow-up.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"139-151"},"PeriodicalIF":5.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential. 育龄妇女使用抗逆转录病毒药物的挑战、风险和机遇。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-27 DOI: 10.1080/14787210.2024.2334054

Alexis C Henderson, Preetam Cholli, Margaret A Lampe, Athena P Kourtis

{"title":"Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential.","authors":"Alexis C Henderson, Preetam Cholli, Margaret A Lampe, Athena P Kourtis","doi":"10.1080/14787210.2024.2334054","DOIUrl":"10.1080/14787210.2024.2334054","url":null,"abstract":"Introduction: The HIV/AIDS epidemic has been one of the greatest challenges in global health, significantly affecting women of reproductive potential. Considerable advances in antiretroviral therapy for women living with HIV have contributed to improvements in quality of life, better reproductive and birth outcomes, and a reduced risk of perinatal transmission.Areas covered: Despite the progress made, persistent challenges in access and adherence to antiretroviral drugs may limit their benefits for some women. More pharmacokinetic and safety studies in pregnant and lactating women are urgently needed, as are prospective surveillance systems to evaluate associations between fetal and infant antiretroviral exposures, drug-drug interactions, and pregnancy outcomes.Expert opinion: Multipurpose technologies, such as combined HIV and other STI or unintended pregnancy prevention, and innovative delivery methods, such as the development of long-acting antiretrovirals, have the potential to reduce adherence challenges and enhance quality of life for women with HIV. Parallel advances in drug safety testing and surveillance are needed to ensure the health and safety of women with or at risk for HIV and children at risk for perinatal transmission.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"153-167"},"PeriodicalIF":4.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140189614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice. 同种异体造血干细胞移植中巨细胞病毒感染的来替莫韦：在临床实践中有效使用的提示和注意事项。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-01 DOI: 10.1080/14787210.2024.2322439

Akihiro Ohmoto, Shigeo Fuji

{"title":"Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice.","authors":"Akihiro Ohmoto, Shigeo Fuji","doi":"10.1080/14787210.2024.2322439","DOIUrl":"10.1080/14787210.2024.2322439","url":null,"abstract":"Introduction: Cytomegalovirus (CMV) infection remains a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). While conventional antiviral agents such as ganciclovir can be used for CMV prophylaxis, toxicities such as myelosuppression are a major concern.Area covered: This work aimed to summarize the latest information and practical issues regarding a new anti-CMV agent, letermovir (LET).Expert opinion: LET inhibits CMV replication by binding to components of the DNA terminase complex. A phase 3 trial in allo-HSCT recipients showed a reduced incidence of clinically significant CMV infection in the LET group. In 2017, this agent was first approved for CMV prophylaxis in adult CMV-seropositive allo-HSCT recipients in the United States, and is now used worldwide. While LET has an excellent toxicity profile, there are issues to be aware of, such as interactions with other drug classes (e.g. immunosuppressants and antifungals) and reactivation of CMV infection following LET cessation. While LET is the current standard of care for CMV prophylaxis, there are no established protocols for preemptive treatment of asymptomatic CMV viremia or for treatment of developed CMV disease. Further research is needed to maximize the benefits of LET, including the discovery of biomarkers.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"169-178"},"PeriodicalIF":5.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0